ClinicalTrials.gg
CompletedNCT00294112Updated Apr 2, 2020

Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease

A Phase 2 interventional study of Prochymal™ adult human mesenchymal stem cells and adult human mesenchymal stem cells in Crohn's Disease, sponsored by Mesoblast, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-04-02.

Sponsored by Mesoblast, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2006, 20 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
445th of 528
10 · median 60
Started
2006
with 21 others
Phase 2
141 of 660
23 open now
Registered
59th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 445th largest by enrollment of the 528 interventional ones that give a count, is one of 22 that started in 2006, is one of 141 in phase 2, and was the 59th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory. MSCs have shown the ability to find injured tissue, reduce and control inflammation, and assist in tissue repair.

Prochymal™ MSCs will be infused into patients with moderate-to-severe Crohn's disease. Infusions will occur on two separate days, 7-10 days apart. Patients will be monitored for reduced Crohn's disease symptoms.

Read the detailed description

Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory. MSCs have shown the ability to find injured tissue, reduce and control inflammation, and assist in tissue repair.

Prochymal™ MSCs will be infused into patients with moderate-to-severe Crohn's disease. Infusions will occur on two separate days, 7-10 days apart. Patients will be monitored for reduced Crohn's disease symptoms. Patients will receive high or low dose. Study is open label.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • mesenchymal stem cells
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be 18 to 70 years of age, inclusive.
  2. If female and of child-bearing age, subject must be non-pregnant, non-breast-feeding, and use adequate . If male, subject must use adequate contraception.
  3. Subject must have endoscopically or radiographically active Crohn's disease
  4. Subject must have a Crohn's disease activity index (CDAI) of at least 220.
  5. Subject must have a C-reactive protein (CRP) of at least 5 mg/l.
  6. Subject must have ileocolitis, colitis, or ileitis.
  7. At some time during the course of the subject's Crohn's disease (CD), subject must have received both and agents (for example, azothioprine, 6-mercaptopurine, or methotrexate) which did not control the CD.
  8. Subject may be receiving antibiotics, 5-aminosalicylic acid, azathioprine, 6-mercaptopurine, methotrexate, prednisone, or any similar drugs at the time of enrollment.

    • The dose of 5-aminosalicylic acid (5-ASA) must have been stable for at least 4 weeks prior to enrollment.
    • The dose of steroids must have been stable for at least 4 weeks prior to enrollment.
    • The dose of antibiotics must have been stable for at least 4 weeks prior to enrollment.
    • The dose of immunosuppressants (for example, azathioprine, 6-mercaptopurine [6-MP], or methotrexate) must have been stable for at least 8 weeks prior to enrollment and the subject on therapy for at least three months prior to enrollment.
  9. Subject must have adequate renal function as defined by a calculated of greater than 30 ml/min using the Cockcroft-Gault equation, and a serum creatinine concentration of less than 2.0 mg/dl.
  10. Subject must be available for all specified assessments at the study site through day 30.
  11. Subject must provide a written form (ICF) and authorization for use of and disclosure of personal health information (PHI).

Exclusion criteria

Exclusion Criteria:

  1. Subject has any alcohol or substance abuse within 6 months of randomization.
  2. Subject has evidence of fibrostenotic obstructive Crohn's disease.
  3. Subject has an active infection with or or C.
  4. Subject has had surgery or trauma within 28 d prior to enrollment.
  5. Subject has a known allergy to computed tomography (CT) contrast agents.
  6. Subject has a known allergy to bovine or porcine products.
  7. Subject has body mass greater than 150 kg.
  8. Subject has had a stricture of the bowel requiring hospitalization within 6 months prior to enrollment.
  9. Subject has had bowel surgery other than perianal (for example, fistulotomy, seton placement, or abscess drainage) within 6 months prior to enrollment.
  10. Subject has received infliximab; adalimumab; or other antibody, protein, or biological therapy not specifically approved by the United States Food and Drug Administration (FDA) for Crohn's disease for 90 days (d) prior to enrollment in study.
  11. Subject has received prednisone greater than 20 mg/d at any time 28 d prior to enrollment in study.
  12. Subject has a permanent colostomy or ileostomy.
  13. Subject has (AST), alkaline phosphatase (ALP), or alanine transaminase (ALT) more than 2.5 times the at screening.
  14. Subject has evidence of active other than resected basal or squamous cell carcinoma of the skin, or prior history of active malignancy that has not been in remission for at least 5 years.
  15. Subject has history of bacteremia or other serious bacterial or fungal infection in past 3 months other than a treated urinary tract infection or drained perianal abscess.
  16. Subject has received an agent (IA)-an agent or device not approved by FDA for marketed use in any indication-within 90 d (or 5 half-lives, whichever is longer) of randomization.
  17. Subject has cardiopulmonary disease that, in the opinion of the Investigator, is either unstable or severe enough to justify exclusion from this study.
  18. Subject has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would make participation in the study unsafe.
  19. Subject has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the subject. Such excluding conditions might include, for example, uncontrolled infection, right heart failure, pulmonary hypertension.
  20. Subject has unstable arrhythmia.
  21. Subject is unwilling or unable to adhere to requirements of protocols.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    High dose

    High dose (8 million cells per kg of body weight)

    Drug: Prochymal™ adult human mesenchymal stem cells · Drug: adult human mesenchymal stem cells

  • Experimental
    Low dose

    Low dose: 2 million cells per kg body weight

    Drug: Prochymal™ adult human mesenchymal stem cells · Drug: adult human mesenchymal stem cells

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Reduction in Crohn's Disease Activity Index (CDAI) of at Least 100 Points

    The CDAI is a composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more disease activity.

    Time frame: 28 days

Secondary outcomes

  1. Number of Participants with Reduction in CDAI of at Least 70 points

    The CDAI is a composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more disease activity.

    Time frame: 28 days

  2. Improvement as Assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)

    The IBDQ measures disease-specific quality of life by assessing bowel symptoms, systemic symptoms, emotional function, and social function. Subscores can range from 1 (worst) to 7 (best). The total IBDQ is calculated as the sum of the responses to the individual IBDQ questions. The total score ranges from 32 to 224. An increase in score from baseline indicates improvement.

    Time frame: 28 days

  3. Time to Improvement in IBDQ

    Time frame: 28 days

  4. Number of Participants with Reduction of at Least 50% in Fistulas in Participants with Fistulas Draining Under Moderate Compression

    Time frame: 28 days

  5. Number of Participants with Induction of Remission as Defined by Reduction of CDAI to Below 150

    The CDAI is a composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more disease activity.

    Time frame: 28 days

  6. Time to Reduction in CDAI of at Least 100 Points

    Time frame: 28 days

  7. Time to Reduction in CDAI of at Least 70 Points

    Time frame: 28 days

  8. Time to Induction of Remission as Defined by Reduction of CDAI to Below 150.

    Time frame: 28 days

  9. Number of Participants with Adverse Events

    Time frame: Up to approximately 2 years

07

Study locations

4 sites
  • Osiris Clinical Site
    Baton Rouge, Louisiana 70801, United States
  • Osiris Clinical Site
    Charlotte, North Carolina 28105, United States
  • Osiris Clinical Site
    Pittsburgh, Pennsylvania 15106, United States
  • Osiris Clinical Site
    Richmond, Virginia 23173, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2006 to primary completion in Jul 2006, 4 months.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 4 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2006
First posted
Feb 20, 2006
StartActual
Mar 13, 2006
Primary completionActual
Jul 21, 2006
CompletionActual
Jul 21, 2006
Last update
Apr 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00294112
Lead sponsor
Mesoblast, Inc.
Responsible party
Sponsor
First posted
Feb 20, 2006
Start date
Mar 13, 2006
Primary completion
Jul 21, 2006
Completion
Jul 21, 2006
Last update
Apr 2, 2020

Study contacts

Mahboob Rahman, MD
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion